Protagonist Therapeutics, Inc. - Common Stock (PTGX)

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes.

Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.

Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.

FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's overall benefit.

U.S. markets were rattled on Friday after President Trump reignited trade tensions with China, triggering the sharpest sell-off since April. Tech and AI stocks led the decline, while gold and Treasuries saw renewed safe-haven demand.

The company could soon be swallowed by a very large peer -- which also happens to be a business partner.

Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio.

Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.

Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.

The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.

Interesting Technical Analysis finding for PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX): Indications Suggest NASDAQ:PTGX Could Be on the Verge of a Breakout.

Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.

Should you consider PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) for high growth investing? A fundamental and technical analysis of (NASDAQ:PTGX).

Mid-cap stocks were top performers last week. D-Wave, Protagonist, Veren, IonQ, Rigetti, Semtech, Orla Mining, and Hesai all saw significant gains.